*Refresh the page if the below document does not appear.
A parliamentary committee has asked the Centre to provide free Cancer treatment for patients from middle-class households through a government-funded health insurance scheme and to decrease the cancer diagnostics and treatment services in government and private hospitals.
The US drug regulatory authority has given final approval to Zydus Lifesciences to market their two new capsules named Silodosin capsules (4 mg and 8 mg) and Pregabalin capsules (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg).
Entod pharmaceuticals have announced that the firm is all set to launch its GLO ophthalmic subspeciality division to further expand its business. This division will be focused on the treatment of the major cause of blindness in India, Glaucoma.
Seagen’s plan to expand its Adcetris’ drug market is on track following positive results from the Phase II study. On Monday, the biopharma firm announced Adcetris hit the mark in a multi-part, midstage trial for advanced and early-stage classical Hodgkin lymphoma (cHL).
According to some sources, big buyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are some of those who have been approached to buy the Gland Pharmaceuticals owned by Fosun.
A few months after the Swiss company announced that its diagnostics division head would take over as chief executive officer (CEO) next year, the present head Bill Anderson has decided to quit the firm to look for opportunities outside of Roche.
As mentioned by the company, US-based
medical device manufacturer Boston
Scientific Corp. is set to make a partial offer
for a majority stake of up to 65% in Chinese
medical technology company Acotec
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website